LPTI Longport Inc (CE)

Longport, Inc. (OTC PK:LPTI), a medical technology specialist in high-frequency high resolution ultrasound imaging, today announced information on orders received since the beginning of 2008. Sales activity by the end of the third quarter has totaled 33 EPISCAN systems. All of the units have been sold into wound prevention/assessment. Of the last ten sales, 3 systems were into long-term care, and 7 systems were sold into acute hospitals. Sales into acute hospitals were a direct result of the new CMS Ruling, which has now gone into effect. This CMS rule change states that Medicaid and Medicare will no longer be held responsible for �reasonably preventable� hospital-acquired pressure ulcers. This rule is expected to benefit Longport�s efforts in getting the EPISCAN I-200 ultrasound scanner accepted in hospitals for use in pressure ulcer prevention. The EPISCAN is an assessment tool which when used in conjunction with standard of care visual skin assessment provides more reliable skin assessment and improved documentation. The images the scanner generates can also help facilities to initiate targeted preventative intervention earlier, frequently avoiding pressure ulcers from developing. Paul Wilson, President of Longport, Inc. said �The Company believes that the door into acute care is beginning to open for the EPISCAN. We project acute care will become one of Longport�s largest markets. In addition to the sales reported, the Company has received inquiries from numerous acute hospitals each potentially looking to purchase multiple systems.� Longport will also be exhibiting at the Clinical Symposium on Advances in Skin and Wound Care, to be held October 26 - 30 in Las Vegas. This symposium targets nurses, physicians, podiatrists, physical therapists, dietitians, and others who manage skin and wound care patients across the continuum of health care. Longport will be exhibiting at Booth 213. About Longport, Inc. Longport, Inc. of Glen Mills, Pennsylvania, is a medical technology company that specializes in high resolution ultrasound imaging. After several years and a multi-million dollar investment in the technology, Longport has secured patents, copyrights and FDA permission to market. The Company�s technology has been used to engineer a unique high resolution ultrasound imaging system. For further information please contact Longport, Inc. at 1-800-289-6863 or visit our website at www.longportinc.com. Forward-looking Information and the Private Securities Litigation Reform Act of 1995 Certain statements in this press release, including statements concerning product development milestones and anticipated events, are �forward-looking statements� within the Private Litigation Reform Act of 1995. Forward Looking Statements are based on the opinions and estimates of management at the time the statements are made and are subject to certain risks and uncertainties that could cause actual results to differ materially from those anticipated in the forward-looking statements. The words �believe,� �expect,� �intend,� �anticipate,� variations of such words, and similar expressions identify forward-looking statements, but their absence does not mean that the statement is not forward-looking. These statements are not guarantees of future performance and are subject to certain risks, uncertainties and assumptions that are difficult to predict. Factors that could affect Longport�s actual results include, among others, uncertainties as to the Company�s ability to manage potential problems, delays or anticipated expenses, including problems, delays or expenses involving manufacturing. Readers are cautioned not to place undue reliance upon these forward-looking statements that speak only to the date of this release. Reference is made to Longport�s 2004 annual report on Form 10-K filed with the Securities and Exchange Commission for a more definitive description of such factors. Longport, Inc. undertakes no obligation to update publicly any forward-looking statements to reflect new information, events or circumstances after the date of this release or to reflect the occurrence of unanticipated events.